Prognostic factors in resistant hypertension: implications for cardiovascular risk stratification and therapeutic management

References

• Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360(9349), 1903–1913 (2002).
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A et al. Management of Arterial Hypertension of the European Society of Hypertension European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25(6), 1105–1187 (2007).
   PubMed Web of Science ®Google Scholar
• Pimenta E. Update on diagnosis and treatment of resistant hypertension. Iran. J. Kidney Dis. 5(4), 215–227 (2011).
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Jones D, Textor S et al.; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117(25), e510–e526 (2008).
   PubMed Web of Science ®Google Scholar
• Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension 57(6), 1076–1080 (2011).
   PubMed Web of Science ®Google Scholar
• de la Sierra A, Segura J, Banegas JR et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 57(5), 898–902 (2011).
   PubMed Web of Science ®Google Scholar
• Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 124(9), 1046–1058 (2011).
   PubMed Web of Science ®Google Scholar
• Muxfeldt ES, Salles GF. Pulse pressure or dipping pattern: which one is a better cardiovascular risk marker in resistant hypertension? J. Hypertens. 26(5), 878–884 (2008).
   PubMed Web of Science ®Google Scholar
• Daugherty SL, Powers JD, Magid DJ et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 125(13), 1635–1642 (2012).
   PubMed Web of Science ®Google Scholar
• Redon J, Campos C, Narciso ML, Rodicio JL, Pascual JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 31(2), 712–718 (1998).
   PubMed Web of Science ®Google Scholar
• Pierdomenico SD, Lapenna D, Bucci A et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am. J. Hypertens. 18(11), 1422–1428 (2005).
   PubMed Web of Science ®Google Scholar
• Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch. Intern. Med. 168(21), 2340–2346 (2008).
   PubMed Web of Science ®Google Scholar
• Muxfeldt ES, Cardoso CR, Salles GF. Prognostic value of nocturnal blood pressure reduction in resistant hypertension. Arch. Intern. Med. 169(9), 874–880 (2009).
   PubMed Web of Science ®Google Scholar
• Salles GF, Cardoso CR, Muxfeldt ES. Prognostic value of ventricular repolarization prolongation in resistant hypertension: a prospective cohort study. J. Hypertens. 27(5), 1094–1101 (2009).
   PubMed Web of Science ®Google Scholar
• Salles GF, Cardoso CR, Fiszman R, Muxfeldt ES. Prognostic impact of baseline and serial changes in ECG left ventricular hypertrophy in resistant hypertension. Am. Heart J. 159(5), 833–840 (2010).
   PubMed Web of Science ®Google Scholar
• Salles GF, Cardoso CR, Fiszman R, Muxfeldt ES. Prognostic significance of baseline and serial changes in ECG strain pattern in resistant hypertension. J. Hypertens. 28(8), 1715–1723 (2010).
   PubMed Web of Science ®Google Scholar
• Muxfeldt ES, Cardoso CR, Dias VB, Nascimento AC, Salles GF. Prognostic impact of the ambulatory arterial stiffness index in resistant hypertension. J. Hypertens. 28(7), 1547–1553 (2010).
   PubMed Web of Science ®Google Scholar
• Salles GF, Cardoso CR, Fiszman R, Muxfeldt ES. Prognostic importance of baseline and serial changes in microalbuminuria in patients with resistant hypertension. Atherosclerosis 216(1), 199–204 (2011).
   PubMed Web of Science ®Google Scholar
• Salles GF, Cardoso CR, Pereira VS, Fiszman R, Muxfeldt ES. Prognostic significance of a reduced glomerular filtration rate and interaction with microalbuminuria in resistant hypertension: a cohort study. J. Hypertens. 29(10), 2014–2023 (2011).
   PubMed Web of Science ®Google Scholar
• Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N. Engl. J. Med. 354(22), 2368–2374 (2006).
   PubMed Web of Science ®Google Scholar
• Muxfeldt ES, Bloch KV, Nogueira AR, Salles GF. Twenty-four hour ambulatory blood pressure monitoring pattern of resistant hypertension. Blood Press. Monit. 8(5), 181–185 (2003).
   PubMedGoogle Scholar
• Muxfeldt ES, Bloch KV, Nogueira AR, Salles GF. True resistant hypertension: is it possible to be recognized in the office? Am. J. Hypertens. 18(12 Pt 1), 1534–1540 (2005).
   PubMed Web of Science ®Google Scholar
• Ohkubo T, Imai Y, Tsuji I et al. Prediction of mortality by ambulatory blood pressure monitoring versus screening blood pressure measurements: a pilot study in Ohasama. J. Hypertens. 15(4), 357–364 (1997).
   PubMed Web of Science ®Google Scholar
• Hansen TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pedersen C. Ambulatory blood pressure and mortality: a population-based study. Hypertension 45(4), 499–504 (2005).
   PubMed Web of Science ®Google Scholar
• Boggia J, Li Y, Thijs L et al.; International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes (IDACO) investigators. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet 370(9594), 1219–1229 (2007).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Thijs L, Fagard R et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 282(6), 539–546 (1999).
   PubMed Web of Science ®Google Scholar
• Clement DL, De Buyzere ML, De Bacquer DA et al.; Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N. Engl. J. Med. 348(24), 2407–2415 (2003).
   PubMed Web of Science ®Google Scholar
• Dolan E, Stanton A, Thijs L et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 46(1), 156–161 (2005).
   PubMed Web of Science ®Google Scholar
• Sega R, Facchetti R, Bombelli M et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 111(14), 1777–1783 (2005).
   PubMed Web of Science ®Google Scholar
• Gonçalves SC, Martinez D, Gus M et al. Obstructive sleep apnea and resistant hypertension: a case–control study. Chest 132(6), 1858–1862 (2007).
   PubMed Web of Science ®Google Scholar
• Pimenta E, Gaddam KK, Pratt-Ubunama MN et al. Aldosterone excess and resistance to 24-h blood pressure control. J. Hypertens. 25(10), 2131–2137 (2007).
   PubMed Web of Science ®Google Scholar
• Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N. Engl. J. Med. 353(19), 2034–2041 (2005).
   PubMed Web of Science ®Google Scholar
• Calhoun DA. Aldosterone and cardiovascular disease: smoke and fire. Circulation 114(24), 2572–2574 (2006).
   PubMed Web of Science ®Google Scholar
• Fagard RH, Celis H, Thijs L et al. Daytime and night-time blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 51(1), 55–61 (2008).
   PubMed Web of Science ®Google Scholar
• Li Y, Wang JG, Dolan E et al. Ambulatory arterial stiffness index derived from 24-hour ambulatory blood pressure monitoring. Hypertension 47(3), 359–364 (2006).
   PubMed Web of Science ®Google Scholar
• Hansen TW, Staessen JA, Torp-Pedersen C et al. Ambulatory arterial stiffness index predicts stroke in a general population. J. Hypertens. 24(11), 2247–2253 (2006).
   PubMed Web of Science ®Google Scholar
• Dolan E, Thijs L, Li Y et al. Ambulatory arterial stiffness index as a predictor of cardiovascular mortality in the Dublin Outcome Study. Hypertension 47(3), 365–370 (2006).
   PubMed Web of Science ®Google Scholar
• Kikuya M, Staessen JA, Ohkubo T et al. Ambulatory arterial stiffness index and 24-hour ambulatory pulse pressure as predictors of mortality in Ohasama, Japan. Stroke. 38(4), 1161–1166 (2007).
   PubMed Web of Science ®Google Scholar
• Ben-Dov IZ, Gavish B, Kark JD, Mekler J, Bursztyn M. A modified ambulatory arterial stiffness index is independently associated with all-cause mortality. J. Hum. Hypertens. 22(11), 761–766 (2008).
   PubMed Web of Science ®Google Scholar
• Palmas W, Pickering TG, Teresi J et al. Ambulatory blood pressure monitoring and all-cause mortality in elderly people with diabetes mellitus. Hypertension 53(2), 120–127 (2009).
   PubMed Web of Science ®Google Scholar
• Muxfeldt ES, Fiszman R, Castelpoggi CH, Salles GF. Ambulatory arterial stiffness index or pulse pressure: which correlates better with arterial stiffness in resistant hypertension? Hypertens. Res. 31(4), 607–613 (2008).
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Fernández JR, Calvo C. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension 51(1), 69–76 (2008).
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Fernández JR. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J. Am. Coll. Cardiol. 58(11), 1165–1173 (2011).
   PubMed Web of Science ®Google Scholar
• Rubulis A, Jensen J, Lundahl G, Tapanainen J, Bergfeldt L. Ischemia induces aggravation of baseline repolarization abnormalities in left ventricular hypertrophy: a deleterious interaction. J. Appl. Physiol. 101(1), 102–110 (2006).
   PubMed Web of Science ®Google Scholar
• Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am. Heart J. 141(3), 334–341 (2001).
   PubMed Web of Science ®Google Scholar
• Oikarinen L, Nieminen MS, Toivonen L et al.; LIFE Study Investigators. Relation of QT interval and QT dispersion to regression of echocardiographic and ECG left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study. Am. Heart J. 145(5), 919–925 (2003).
   PubMed Web of Science ®Google Scholar
• Chapman N, Mayet J, Ozkor M, Lampe FC, Thom SA, Poulter NR. QT intervals and QT dispersion as measures of left ventricular hypertrophy in an unselected hypertensive population. Am. J. Hypertens. 14(5 Pt 1), 455–462 (2001).
   PubMed Web of Science ®Google Scholar
• Schillaci G, Pirro M, Ronti T et al. Prognostic impact of prolonged ventricular repolarization in hypertension. Arch. Intern. Med. 166(8), 909–913 (2006).
   PubMedGoogle Scholar
• Oikarinen L, Nieminen MS, Viitasalo M et al.; LIFE Study Investigators. QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 43(5), 1029–1034 (2004).
   PubMed Web of Science ®Google Scholar
• Salles GF, Cardoso CR, Leocadio SM, Muxfeldt ES. Recent ventricular repolarization markers in resistant hypertension: are they different from the traditional QT interval? Am. J. Hypertens. 21(1), 47–53 (2008).
   PubMed Web of Science ®Google Scholar
• Hsieh BP, Pham MX, Froelicher VF. Prognostic value of ECG criteria for left ventricular hypertrophy. Am. Heart J. 150(1), 161–167 (2005).
   PubMed Web of Science ®Google Scholar
• Ishikawa J, Ishikawa S, Kabutoya T et al.; Jichi Medical School Cohort Study Investigators Group. Cornell product left ventricular hypertrophy in electrocardiogram and the risk of stroke in a general population. Hypertension 53(1), 28–34 (2009).
   PubMed Web of Science ®Google Scholar
• Okin PM, Devereux RB, Jern S et al.; LIFE Study Investigators. Regression of ECG left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 292(19), 2343–2349 (2004).
   PubMed Web of Science ®Google Scholar
• Fagard RH, Staessen JA, Thijs L et al.; Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Prognostic significance of ECG voltages and their serial changes in elderly with systolic hypertension. Hypertension 44(4), 459–464 (2004).
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Reboldi G, Angeli F et al.; HEART Survey Study Group. Prognostic value of serial ECG voltage and repolarization changes in essential hypertension: the HEART Survey study. Am. J. Hypertens. 20(9), 997–1004 (2007).
   PubMed Web of Science ®Google Scholar
• Mathew J, Sleight P, Lonn E et al.; Heart Outcomes Prevention Evaluation (HOPE) Investigators. Reduction of cardiovascular risk by regression of ECG markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 104(14), 1615–1621 (2001).
   PubMed Web of Science ®Google Scholar
• Pewsner D, Jüni P, Egger M, Battaglia M, Sundström J, Bachmann LM. Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ 335(7622), 711 (2007).
   PubMed Web of Science ®Google Scholar
• Salles G, Leocádio S, Bloch K, Nogueira AR, Muxfeldt E. Combined QT interval and voltage criteria improve left ventricular hypertrophy detection in resistant hypertension. Hypertension 46(5), 1207–1212 (2005).
   PubMed Web of Science ®Google Scholar
• Antikainen RL, Grodzicki T, Beevers DG, Webster J, Jokelainen JJ, Bulpitt CJ. Left ventricular hypertrophy by Sokolow-Lyon voltage criterion predicts mortality in overweight hypertensive subjects. J. Hum. Hypertens. 23(1), 20–26 (2009).
   PubMed Web of Science ®Google Scholar
• Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Dahlöf B. Baseline characteristics in relation to ECG left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators. Hypertension 36(5), 766–773 (2000).
   PubMed Web of Science ®Google Scholar
• Salles G, Cardoso C, Nogueira AR, Bloch K, Muxfeldt E. Importance of the ECG strain pattern in patients with resistant hypertension. Hypertension 48(3), 437–442 (2006).
   PubMed Web of Science ®Google Scholar
• Okin PM, Devereux RB, Fabsitz RR, Lee ET, Galloway JM, Howard BV; Strong Heart Study. Quantitative assessment of ECG strain predicts increased left ventricular mass: the Strong Heart Study. J. Am. Coll. Cardiol. 40(8), 1395–1400 (2002).
   PubMed Web of Science ®Google Scholar
• Schillaci G, Pirro M, Pasqualini L et al. Prognostic significance of isolated, non-specific left ventricular repolarization abnormalities in hypertension. J. Hypertens. 22(2), 407–414 (2004).
   PubMed Web of Science ®Google Scholar
• Okin PM, Devereux RB, Nieminen MS et al.; LIFE Study Investigators. ECG strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients. Hypertension 44(1), 48–54 (2004).
   PubMed Web of Science ®Google Scholar
• Larsen CT, Dahlin J, Blackburn H et al. Prevalence and prognosis of ECG left ventricular hypertrophy, ST-segment depression and negative T-wave; the Copenhagen City Heart Study. Eur. Heart J. 23(4), 315–324 (2002).
   PubMed Web of Science ®Google Scholar
• Okin PM, Oikarinen L, Viitasalo M et al.; LIFE Study Investigators. Prognostic value of changes in the ECG strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). Circulation 119(14), 1883–1891 (2009).
   PubMed Web of Science ®Google Scholar
• Wachtell K, Ibsen H, Olsen MH et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann. Intern. Med. 139(11), 901–906 (2003).
   PubMed Web of Science ®Google Scholar
• Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 35(4), 898–903 (2000).
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Remuzzi G. Time to abandon microalbuminuria? Kidney Int. 70(7), 1214–1222 (2006).
   PubMed Web of Science ®Google Scholar
• Klausen KP, Scharling H, Jensen G, Jensen JS. New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension 46(1), 33–37 (2005).
   PubMed Web of Science ®Google Scholar
• Redon J. Urinary albumin excretion: lowering the threshold of risk in hypertension. Hypertension 46(1), 19–20 (2005).
   PubMed Web of Science ®Google Scholar
• Ibsen H, Olsen MH, Wachtell K et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 45(2), 198–202 (2005).
   PubMed Web of Science ®Google Scholar
• Levey AS, Cattran D, Friedman A et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am. J. Kidney Dis. 54(2), 205–226 (2009).
   PubMed Web of Science ®Google Scholar
• de Zeeuw D. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney Int. Suppl. 92, S2–S6 (2004).
   Google Scholar
• de Zeeuw D, Remuzzi G, Parving HH et al. Albuminuria, a therapeutic target for cardiovascular protection in Type 2 diabetic patients with nephropathy. Circulation 110(8), 921–927 (2004).
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39(Suppl. 1), S1–S266 (2002).
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Zanchetti A, Julius S et al.; VALUE Investigators. Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial. J. Hypertens. 25(7), 1473–1479 (2007).
   PubMed Web of Science ®Google Scholar
• Castelpoggi CH, Pereira VS, Fiszman R, Cardoso CR, Muxfeldt ES, Salles GF. A blunted decrease in nocturnal blood pressure is independently associated with increased aortic stiffness in patients with resistant hypertension. Hypertens. Res. 32(7), 591–596 (2009).
   PubMed Web of Science ®Google Scholar
• Pabuccu T, Baris N, Ozpelit E, Akdeniz B, Guneri S. The relationship between resistant hypertension and arterial stiffness. Clin. Exp. Hypertens. 34(1), 57–62 (2012).
   PubMed Web of Science ®Google Scholar
• Salles GF, Fiszman R, Cardoso CR, Muxfeldt ES. Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension. Hypertension 50(4), 723–728 (2007).
   PubMed Web of Science ®Google Scholar
• Cuspidi C, Vaccarella A, Negri F, Sala C. Resistant hypertension and left ventricular hypertrophy: an overview. J. Am. Soc. Hypertens. 4(6), 319–324 (2010).
   PubMed Web of Science ®Google Scholar